EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Wenjing Tao iD, Qiwen Fan, Jintao Wei

Current Issues in Molecular Biology · 01.02.2024 · 46 (2) · 1219-1236

DOI: 10.3390/cimb46020078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 01.02.2024. Verfasst von Wenjing Tao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Animal Embryo and Molecular Breeding, Institute of Animal Husbandry and Veterinary, Hubei Academy of Agricultural Sciences, W…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Innovation Center of Agricultural Science and Technology, Youth Foundation of Hubei Academy of Agricultural Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) is a liver disease that remains difficult to predict and diagnose, and the underlying mechanisms are yet to be fully clarified. The gut–liver axis refers to the reciprocal interactions between the gut and the liver, and its homeostasis plays a prominent role in maintaining liver health. It has been recently reported that patients and animals with DILI have a disrupted gut–liver axis, involving altered gut microbiota composition, increased intestinal permeability and lipopolysaccharide translocation, decreased short-chain fatty acids production, and impaired bile acid metabolism homeostasis. The present review will summarize the evidence from both clinical and preclinical studies about the role of the gut–liver axis in the pathogenesis of DILI. Moreover, we will focus attention on the potential therapeutic strategies for DILI based on improving gut–liver axis function, including herbs and phytochemicals, probiotics, fecal microbial transplantation, postbiotics, bile acids, and Farnesoid X receptor agonists.

Schlagwörter

Stichwörter der Autor:innen

bile aciddrug-induced liver injurygut microbiotagut–liver axismetabolites

Autor:innen und Institutionen

  • Hubei Key Laboratory of Animal Embryo and Molecular Breeding, Institute of Animal Husbandry and Veterinary, Hubei Academy of Agricultural Sciences, Wuhan 430064, China.

ORCID-Profile: Wenjing Tao

Förderung

  • Hubei Innovation Center of Agricultural Science and Technology
  • Youth Foundation of Hubei Academy of Agricultural Sciences

Zitieren

APA

Tao, W., Fan, Q., & Wei, J. (2024). Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury. Current Issues in Molecular Biology, 46(2), 1219-1236. https://doi.org/10.3390/cimb46020078

Vancouver

Tao W, Fan Q, Wei J. Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury. Current Issues in Molecular Biology. 2024;46(2):1219-1236. doi:10.3390/cimb46020078

BibTeX
@article{Tao2024,
  author = {Tao, Wenjing and Fan, Qiwen and Wei, Jintao},
  title = {Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury},
  journal = {Current Issues in Molecular Biology},
  year = {2024},
  volume = {46},
  number = {2},
  pages = {1219--1236},
  doi = {10.3390/cimb46020078}
}
Kostenlos starten →